New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2013
09:09 EDTCSCO, JNPR, IBM, ODP, HTGC, SCTY, NVAX, LULU, WMT, KSS, CIENOn The Fly: Pre-market Movers
HIGHER: Novavax (NVAX), up 8% after NEJM publishes positive data from study of flu vaccine... SolarCity (SCTY), up 7.5% after shares were upgraded at RW Baird... Office Depot (ODP), up 2% after stock upgraded at BofA Merrill Lynch... DOWN AFTER EARNINGS: Wal-Mart (WMT), down 1.7%... Kohl's (KSS), down 8%... ALSO LOWER: Hercules Technology (HTGC), down 3% after downgraded at Wunderlich... lululemon (LULU), down 2.7% after downgraded at Sterne Agee... Cisco (CSCO), down 12.5%, after Q1 revenue missed and Q2 guidance lower than expected. Several Cisco peers lower including IBM (IBM), down 1%, Juniper (JNPR), down 3%, and Ciena (CIEN), down 2%.
News For CSCO;KSS;WMT;LULU;NVAX;SCTY;HTGC;ODP;IBM;JNPR;CIEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 15, 2014
09:05 EDTWMTWal-Mart CEO: Future looks bright with the necessary changes
Subscribe for More Information
08:40 EDTNVAXNovavax RSV F Vaccine study evoked polyclonal antibody response
Novavax announced that its RSV F-protein nanoparticle vaccine candidate, or RSV F Vaccine, evoked a polyclonal antibody response to antigenic site II, the same site targeted by the monoclonal antibody palivizumab, resulting in protection from an RSV challenge in an animal model. Researchers at Novavax reported these findings in an online paper published by Vaccine titled: "An insect cell derived respiratory syncytial virus F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization." Greg Glenn, SVP, Research and Development at Novavax stated, "This study further characterizes the immune response to our RSV F Vaccine, including the production of both polyclonal palivizumab competing antibodies that target antigenic site II, as well as other neutralizing antigenic sites on the F-protein. In addition, our ability to assess the safety of our RSV F Vaccine relative to Lot 100 formalin inactivated vaccine, which is known to cause disease enhancement, and to demonstrate that our vaccine's efficacy is equivalent or better than palivizumab, gives us greater confidence that our RSV vaccine candidate will be both safe and effective."
08:23 EDTSCTYSolarCity offers Solar Bonds to investors
Subscribe for More Information
08:07 EDTSCTYSolarCity files automatic mixed securities shelf
Subscribe for More Information
06:49 EDTWMTWal-Mart partners with VUDU for digital movie access offering
Subscribe for More Information
06:15 EDTCSCOCisco lays off 900 in San Jose area, Silicon Valley Business Journal says
Subscribe for More Information
October 14, 2014
15:24 EDTIBMIBM, SAP partner to accelerate Enterprise Cloud adoption
Subscribe for More Information
08:40 EDTNVAXNovavax initiates Phase 2 clinical trial of RSV F vaccine
Novavax announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus, or RSV, F-protein nanoparticle vaccine candidate, in healthy elderly subjects. The trial is a randomized, observer-blinded, placebo-controlled Phase 2 study scheduled to enroll 1,600 elderly subjects at ten sites in the United States. The trial will evaluate the incidence of all respiratory illnesses due to RSV, including medically-attended respiratory illnesses due to RSV, and hospitalizations for respiratory illness due to RSV in community-living elderly adults who have been treated with placebo. The study will also evaluate the safety and immunogenicity of a 135g dose of the RSV F Vaccine compared with placebo. The trial will also estimate the efficacy of the RSV F Vaccine in reducing the incidence of respiratory illnesses due to RSV.
October 13, 2014
14:02 EDTLULUlululemon's Q3 sales tracking below consensus, says ITG Research
Subscribe for More Information
10:58 EDTSCTYSolarCity volatility elevated on wide price movement
Subscribe for More Information
10:08 EDTJNPROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Equal Weight from Overweight at Stephens... CME Group (CME) downgraded to Market Perform from Outperform at Wells Fargo... Cliffs Natural (CLF) downgraded to Neutral from Overweight at JPMorgan... Dana Holding (DAN) downgraded to Sector Perform from Outperform at RBC Capital... Darden (DRI) downgraded to Neutral from Overweight at Piper Jaffray... Dover (DOV) downgraded to Neutral at RW Baird... DryShips (DRYS) downgraded to Underperform from Outperform at Imperial Capital... Infineon (IFNNY) downgraded to Neutral from Overweight at JPMorgan... J.C. Penney (JCP) downgraded to Sell from Neutral at UBS... Johnson Controls (JCI) downgraded to Outperform from Top Pick at RBC Capital... Juniper (JNPR) downgraded to Hold from Buy at Argus... Kennametal (KMT) downgraded to Market Perform from Outperform at Wells Fargo... Masco (MAS) downgraded to Equal Weight from Overweight at Barclays... New Gold (NGD) downgraded to Neutral from Overweight at JPMorgan... ON Semiconductor (ONNN) downgraded to Sector Perform from Outperform at Pacific Crest... PBF Energy (PBF) downgraded to Underweight from Equal Weight at Barclays... Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo... STMicroelectronics (STM) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Sector Perform at Pacific Crest... VOXX International (VOXX) downgraded to Market Perform from Outperform at Cowen.
10:06 EDTKSSJ.C. Penney rises after selecting Home Depot executive as next CEO
Subscribe for More Information
09:23 EDTJNPRHP could buy lower valuation company, says Bernstein
Subscribe for More Information
09:02 EDTWMTWal-Mart October volatility elevated into investment community meeting
Subscribe for More Information
08:03 EDTSCTYSolarCity lowered pricing in California, says JPMorgan
JPMorgan says SolarCity lowered its pricing in California, implementing a fixed price of 15c per watt, down from a prior average of 17c. To reflect the change, SolarCity dropped the NPV of its average new residential deployment to $1.75 per watt from $2.19 historically, the firm notes. JPMorgan cut its Retained Value estimates and dropped its price target for SolarCity shares to $74 from $83. The firm believes the price change could be tied to the proposed compression of rate tiers in 2015, allowing the company to address a larger market. It keeps an Overweight rating on SolarCity.
07:23 EDTJNPRJuniper downgraded to Hold from Buy at Argus
Subscribe for More Information
07:15 EDTWMTNational Association of Corporate Directors to hold a conference
Subscribe for More Information
06:15 EDTKSSJ.C. Penney downgraded to Sell from Neutral at UBS
UBS downgraded its rating on J.C. Penney (JCP) shares to Sell saying the company's 2017 EBITDA target of $1.2B is overly optimistic as it assumes years of market share gains against strong competitors like Macy's (M) and Kohl's (KSS). UBS halved its price target for Penney shares to $5 from $10. The retailer's stock closed Friday down 52c to $7.12.
October 12, 2014
17:55 EDTWMTWal-Mart, DSW could benefit from holiday sales, Barron's says
Wal-Mart (WMT) and DSW (DSW) could benefit from the recent forecast of a 4% increase in holiday spending, Barron's contends in a follow up article. Reference Link
17:20 EDTCSCOGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use